EGFR and non-small cell lung carcinoma: Prospective randomized clinical trials have shown that tyrosine kinase inhibitors (TKI) gefitinib(1–3)and erlotinib(4,5)as initial treatment for EGFR mutation-positive advanced NSCLC improved outcomes compared with chemotherapy.